Navigation Links
New Jersey Center for Prostate Cancer & Urology Among First in Nation to Treat Advanced Prostate Cancer Patients with PROVENGE

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.  PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

"PROVENGE is a revolutionary new treatment that may lead to similar personalized therapies in other cancer types," said Dr. Vincent Lanteri of NJ Center for Prostate Cancer & Urology. "We are pleased to have a new option to offer our patients and to be selected as one of the first facilities treating men with this important new therapy."

"PROVENGE allows patients to use their own cells to help fight cancer," said Dr. Michael Esposito.  "Patients with advanced prostate cancer now have a new option to prolong their lives.  I'm very excited about this and have high hopes for it."

PROVENGE is an autologous (made from a patient's own immune cells) cellular immunotherapy designed to stimulate a patient's immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

Individuals interested in learning whether PROVENGE is an appropriate treatment option should contact New Jersey Center for Prostate Cancer & Urology 201-487-8866 or call 1-877-336-3736.

About New Jersey Center for Prostate Cancer & Urology

The doctors of New Jersey Center for Prostate Cancer and Urology are undisputed experts in the field and have been recognized as 'Top Doctors' by New Jersey Monthly and New York Magazine and selected by Castle Connolly as 'Top Doctors for Cancer' in the country.  With locations in Northern and Central New Jersey, the practice offers patients needing prostate cancer or urological treatment easy access to state-of-the-art urological care close to home.  Offices are located at 255 W. Spring Valley Avenue, Maywood, NJ, at Holy Name Medical Center 718 Teaneck Road, Teaneck NJ, and at Monmouth Medical Center, 255 Third Avenue, Long Branch, NJ.  For more information about New Jersey Center for Prostate Cancer and Urology call (201) 487-8866 or visit

SOURCE New Jersey Center for Prostate Cancer & Urology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharma Elite to Unveil Latest Industry News/Program Agenda with 70+ Expert Speakers at Exclusive Event: Pharma CI Conference, September 13-14, 2011 in New Jersey
2. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
3. Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
4. Mesothelioma Litigation Attorney, Christopher Placitella to Lead Expert Panel on Mass Tort Litigation in New Jersey
5. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
6. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
7. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
8. First Live Web Chat by New Jerseys Princeton HealthCare System Focuses on Womens Health
9. Hospital Room of the Future Debuts in New Jersey
10. Curemark Opens Autism Trials at New Jersey Site
11. Big Pharma Chemists Turning Out in Large Numbers for ChemOutsourcing Extravaganza Event on September 14-16, 2010 at Jersey Shore Beach Resort
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):